Research programme: inflammation therapeutics - Astria Therapeutics
Alternative Names: CAT 1000; CAT 1002; CAT 1040; CAT 1041; CAT 1902; CAT 1904Latest Information Update: 09 Sep 2021
At a glance
- Originator Catabasis Pharmaceuticals
- Developer Astria Therapeutics
- Class Small molecules
- Mechanism of Action NF-kappa B modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Duchenne muscular dystrophy; Inflammation; Inflammatory bowel diseases
Most Recent Events
- 08 Sep 2021 Catabasis Pharmaceuticals is now called Astria Therapeutics
- 28 Feb 2021 No recent reports of development identified for preclinical development in Duchenne muscular dystrophy in USA (PO)
- 04 Nov 2017 No recent reports of development identified for preclinical development in Inflammation in USA (PO)